Valink Therapeutics focusses on synergistic and non-obvious target combinations to create novel multivalent bispecific antibody-drug conjugates (bsADCs) that transform the treatment of solid tumors and other indications.
Valink is a platform therapeutics company focussing on the discovery of bsADCs. The company is a VC-backed & Y Combinator (W21)-incubated spin-out of the University of Oxford, with over $8.5M raised in pre-Seed/Seed capital.
Company Details
- Employees
- 23
- Founded
- -
- Address
- Boston, Massachusetts 02108, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.valinktx.com
- HQ
- Boston, Massachusetts
Valink Therapeutics Questions
Valink Therapeutics's website is http://www.valinktx.com
Valink Therapeutics's LinkedIn profile is https://www.linkedin.com/company/valinktx
Valink Therapeutics has
23 employees.
View email and phone details for 23
employees at Valink Therapeutics.
Valink Therapeutics's industry is
Biotechnology Research
Valink Therapeutics's top competitors are
Laverock Therapeutics,
Autolus Therapeutics,
Mestag Therapeutics,
Achilles Therapeutics Plc,
Engitix Therapeutics,
Nuntius Therapeutics,
Labgenius Therapeutics,
Avacta Therapeutics,
Quell Therapeutics,
F-Star Therapeutics.
Valink Therapeutics's categories are Biotechnology Research
Valink Therapeutics's founding year is 2020
